Evidence map›Paper›PMID 39310108›Full record

ArticleTheranostics2024

Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study.

Niels J van Ruitenbeek, Maike J M Uijen, Chantal M L Driessen, Steffie M B Peters, Bastiaan M Privé, Adriana C H van Engen-van Grunsven, Mark W Konijnenberg, Martin Gotthardt, James Nagarajah, Carla M L van Herpen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinical Characteristics Associated with High [Nuclear medicine and molecular imaging · 2026
    Article
  4. Incidental detection of PDAC viaFrontiers in nuclear medicine · 2026
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Niels J van RuitenbeekDepartment of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Maike J M UijenDepartment of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Chantal M L DriessenDepartment of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Steffie M B PetersDepartment of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Bastiaan M PrivéDepartment of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Adriana C H van Engen-van GrunsvenDepartment of Pathology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Mark W KonijnenbergDepartment of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Martin GotthardtDepartment of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
James NagarajahDepartment of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Carla M L van HerpenDepartment of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [

Indexed as

LutetiumPositron Emission Tomography Computed TomographyRadioisotopesSalivary Gland NeoplasmsAdultAgedAntigens, SurfaceCarcinoma, Adenoid CysticCarcinoma, DuctalFemaleGlutamate Carboxypeptidase IIHumansMaleMiddle AgedNeoplasm Recurrence, LocalPilot ProjectsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopesRadiopharmaceuticals(177)Lu-PSMA therapyAdenoid cystic carcinomaProstate-specific membrane antigenSalivary duct carcinomaSalivary gland cancer

Identifiers

PMID39310108
PMCPMC11413786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.